Invictus RG’s Impax Laboratories, Inc. IPXL Stock Holding History

Invictus RG’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-1,140	Closed	-$27K	–	842
2016 Q3	$27K	Buy	+1,140	New	+$30.6K	0.02%	548

Other funds holding IPXL

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hound Partners New York $799M AUM 9.54% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

NTC

North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invictus RG's IPXL Position: Q4 2016 in Review

Invictus RG sold out of Impax Laboratories, Inc. (IPXL) in Q4 2016, closing a stake of 1,140 shares — an estimated $27K sold.

Invictus RG first reported a position in IPXL in Q3 2016 and held it in 1 quarter. The position peaked at $27K in Q3 2016. 198 funds tracked by Wall St. Rank hold IPXL as of Q4 2016.

Invictus RG reported no remaining Impax Laboratories, Inc. position as of Q4 2016 after selling out during the quarter.
Invictus RG sold 1,140 Impax Laboratories, Inc. shares in Q4 2016, an estimated $27K.
Invictus RG first reported a position in Impax Laboratories, Inc. in Q3 2016 and held it in 1 quarter.
Invictus RG's Impax Laboratories, Inc. position peaked at $27K in Q3 2016.
198 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q4 2016.

Based on Invictus RG's 13F filing for Q4 2016, filed 14 Feb 2017.